RIPK1 Inhibitor - Pipeline Insight, 2021

Publisher Name :
Date: 10-Feb-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "RIPK1 inhibitor - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in RIPK1 inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

RIPK1 inhibitor Understanding

RIPK1 inhibitor: Overview

RIPK1 is a 76-kDa protein with an amino-terminal (N-terminal) kinase domain, a carboxy-terminal (C-terminal) death domain and an intermediate domain with a RHIM (receptor-interacting protein homotypic interacting motif) that can bind to other RHIM-containing proteins. Receptor?interacting serine/threonine?protein kinase 1 (RIPK1) protein regulates cell death and inflammation and is believed to play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases and cancer. Several RIP1 inhibitors are now progressing in the clinic for the treatment of inflammatory diseases, such as psoriasis, rheumatoid arthritis, and ulcerative colitis, as well for CNS indications such as ALS and Alzheimer's disease. Additional functions of the RIP1 continue to be discovered.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence RIPK1 inhibitor R&D. The therapies under development are focused on novel approaches for RIPK1 inhibitor.

RIPK1 inhibitor Emerging Drugs Chapters

This segment of the RIPK1 inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

RIPK1 inhibitor Emerging Drugs

- DNL-788: Denali Therapeutics / Sanofi

DNL-788 is a small molecule inhibitor of the RIPK1 protein that are able to cross the protective blood-brain-barrier and reach the brain. It is in Phase I clinical studies for Alzheimer's disease, Amyotrophic lateral sclerosis, and Multiple sclerosis. Data from the Phase 1 study in healthy volunteer subjects display an encouraging profile, as the molecule appears safe and tolerable at tested doses. Denali partner Sanofi is responsible for development of DNL758 and is currently planning further clinical studies in multiple indications based on successful Phase 1 data.

- GSK2982772: GlaxoSmithKline

GSK2982772 is the potential first oral, monoselective, ATP competitive, small?molecule inhibitor of RIPK1 and necroptosis to advance into human clinical studies. GSK2982772 binds in an allosteric pocket of the RIPK1 kinase domain and is a potent inhibitor of RIPK1?mediated cell death and cytokine production in preclinical models. The drug is in Phase I clinical studies for the treatment of Plaque psoriasis.

Further product details are provided in the report……..

RIPK1 inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different RIPK1 inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players working on RIPK1 inhibitor

There are approx. 4+ key companies which are developing the RIPK1 inhibitor. The companies which have their RIPK1 inhibitor drug candidates in the most advanced stage, i.e. Phase I include, Denali Therapeutics / Sanofi.

- Phases

DelveInsight's report covers around 6+ products under different phases of clinical development like

- Late-stage products (Phase III and

- Mid-stage products (Phase II and

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

RIPK1 inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Infusion

- Intradermal

- Intramuscular

- Intranasal

- Intravaginal

- Oral

- Parenteral

- Subcutaneous

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Vaccines

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

RIPK1 inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses RIPK1 inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging RIPK1 inhibitor drugs.

RIPK1 inhibitor Report Insights

- RIPK1 inhibitor Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

RIPK1 inhibitor Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing RIPK1 inhibitor drugs?

- How many RIPK1 inhibitor drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for RIPK1 inhibitor?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the RIPK1 inhibitor therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for RIPK1 inhibitor and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Denali Therapeutics

- Sanofi

- Voronoi

- GenFleet Therapeutics

- GlaxoSmithKline

Key Products

- DNL-788

- Eclitasertib

- VRN-04

- GFH-312

- GSK2982772

RIPK1 Inhibitor - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
RIPK1 inhibitor: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
RIPK1 inhibitor - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• RIPK1 inhibitor companies' collaborations, Licensing, Acquisition -Deal Value Trends
RIPK1 inhibitor Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
DNL-788: Denali Therapeutics / Sanofi
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
VRN-04: Voronoi
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
RIPK1 inhibitor Key Companies
RIPK1 inhibitor Key Products
RIPK1 inhibitor- Unmet Needs
RIPK1 inhibitor- Market Drivers and Barriers
RIPK1 inhibitor- Future Perspectives and Conclusion
RIPK1 inhibitor Analyst Views
RIPK1 inhibitor Key Companies
Appendix

List of Tables

Table 1 Total Products for RIPK1 inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for RIPK1 inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Autism Spectrum Disorder Market Growth (Status and Outlook) 2021-2026
    Published: 17-Mar-2021        Price: US 3660 Onwards        Pages: 117
    According to this latest study, the 2021 growth of Autism Spectrum Disorder will have significant change from previous year. By the most conservative estimates of global Autism Spectrum Disorder market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 384400 million in 2020. Over the next five years the Autism Spectrum Disorder market will register a 17.9% CAGR in terms of revenue, the global market size will reach US$ 743920 million by 2026. ......
  • Global Gabapentin Market Growth 2021-2026
    Published: 16-Mar-2021        Price: US 3660 Onwards        Pages: 159
    According to this latest study, the 2021 growth of Gabapentin will have significant change from previous year. By the most conservative estimates of global Gabapentin market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 1482.5 million in 2020. Over the next five years the Gabapentin market will register a 1.9% CAGR in terms of revenue, the global market size will reach US$ 1596.4 million by 2026. This report presents a comprehensi......
  • Global Restless Legs Syndrome Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery
    Published: 16-Mar-2021        Price: US 3500 Onwards        Pages: 116
    Based on the Restless Legs Syndrome market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analy......
  • Global Gabapentin Market Research Report 2021
    Published: 17-Feb-2021        Price: US 2900 Onwards        Pages: 120
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Capsule - Tablet Segment by Application - Epilepsy - Neuropathic Pain - Restle......
  • Global Gabapentin Market Analysis 2016-2020 and Forecast 2021-2026
    Published: 13-Feb-2021        Price: US 2980 Onwards        Pages: 85
    Snapshot Gabapentin is an anti-epileptic medication, also called an anticonvulsant. It affects chemicals and nerves in the body that are involved in the cause of seizures and some types of pain. The global Gabapentin market size is estimated at xxx million USD with a CAGR xx% from 2016-2020 and is expected to reach xxx Million USD in 2021 with a CAGR xx% from 2021 to 2026. The report begins from overview of Industry Chain structure, and describes industry environment, then ana......
  • Global Biopolar Disorder Therapeutics Market Research Report 2021
    Published: 10-Feb-2021        Price: US 2900 Onwards        Pages: 92
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Mood Stabilizers - Antipsychotic Drugs - Antidepressant Drugs - Others Segment by App......
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pi......
  • Chronic Traumatic Encephalopathy - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Chronic Traumatic Encephalopathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chronic traumatic encephalopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geogra......
  • Small Fiber Neuropathy - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Small Fiber Neuropathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Small Fiber Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs